August 2026 in “European Journal of Endocrinology” This case report highlights the growing trend of adolescents using Finasteride off-label for early hair loss, driven by online misinformation and psychological distress, despite potential side effects and hormonal concerns.
1 citations
,
March 2015 in “Hair transplant forum international” This article discusses the FDA approval history of finasteride and does not report new research findings.
January 2016 in “Hair transplant forum international” This abstract provides a brief introduction to Propecia® (finasteride 1mg) but reports no new research findings.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” In this report, the European Medicines Agency confirmed in 2025 that finasteride, a drug used to treat hair loss in men, is linked to suicidal thoughts, a concern previously raised by patient advocacy groups.
44 citations
,
April 2015 in “PubMed” This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.